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Abstract 
Background:  
Cadmium has been associated with increased risk of cardiovascular disease (CVD) in 
observational studies, however there has been a limited focus on this relationship in women. 
Objectives:  
This study investigated the association of urinary cadmium (UCd) concentrations with CVD 
outcomes and all-cause mortality in elderly Western Australian (WA) women. 
Methods:  
UCd excretion was measured at baseline in 1359 women, mean age 75.2 ± 2.7 years and 14.5 
years of atherosclerotic vascular disease (ASVD) hospitalisations and deaths, including both 
the principle cause of death and all associated causes of death. Health outcome data were 
retrieved from the Western Australian Data Linkage System. Cox regression analysis was 
used to estimate hazard ratios of ASVD and all-cause mortality. UCd was ln-transformed and 
models were adjusted for demographic and CVD risk factors.  
Results:  
Median (IQR) concentration of UCd was 0.18 (0.09-0.32) µg/L. In multivariable-adjusted 
analyses per ln unit (equivalent to ~2.7 fold) increase in UCd, there was a 36% increase in the 
risk of death from heart failure and 17% increase in the risk of a heart failure event, 
respectively (HR = 1.36, 95% CI 1.11-1.67; HR = 1.17, 95% CI 1.01- 1.35). When analyses 
were restricted to never smokers the relationship between UCd and death from heart failure 
remained (HR 1.29, 95% CI 1.01-1.63). 
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Conclusions:  
This study suggests that even at low levels of exposure cadmium may be associated with 
heart failure hospitalisations and deaths in older women, however given the dilute nature of 
these urine samples, the results must be interpreted with caution. 
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Introduction 
Cadmium is a widespread heavy metal released in industrial and agricultural processes and 
has been associated with many serious chronic diseases (Nawrot et al., 2010). Environmental 
exposure to cadmium is mainly due to exposure to tobacco smoke and diet, with diet being 
the main source of cadmium in non-smokers (Nawrot et al., 2010).  Low environmental 
exposure to cadmium has been found to increase the risk of adverse health outcomes 
including decreased bone mineral density (Gallagher et al., 2008), impaired kidney function 
(Olsson et al., 2002) and various cancers (Åkesson et al., 2012; McElroy et al., 2006). An 
Australian study by Hinwood et al. (2013), examined exposure in 173 pregnant women and 
reported that one third had urinary cadmium concentrations ≥ 1 µg/g creatinine, which 
indicated an increased risk of health effects in this population. In older Australian women 
lower concentrations of urinary cadmium were reported, however, an association between 
urinary cadmium and decreased bone mineral density was still present at this low level of 
exposure (Callan et al., 2015).  
 
A limited number of longitudinal studies of cadmium exposure, all-cause mortality and 
cardiovascular disease have been conducted, with most studied cohorts residing in the United 
States (Menke et al., 2009; Tellez-Plaza et al., 2013aa; Tellez-Plaza et al., 2013bb; Tellez-
Plaza et al., 2012) or Japan (Nakagawa et al., 2006; Suwazono et al., 2014).  
 
A recent meta-analysis calculated overall HRs for all-cause mortality (6 studies) and CVD 
mortality (5 studies) associated with increased urinary cadmium to be 1.44 (95% CI 1.25, 
1.64) and 1.57 (95% CI 1.27, 1.95), respectively (Larsson and Wolk, 2015). When the 
analysis was restricted to the four studies that had undertaken subgroup analysis by sex, the 
HR for all-cause mortality for women in the highest vs lowest category of urinary cadmium 
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concentration was 1.50 (95% CI 1.08, 2.08) (Larsson and Wolk, 2015). A US study using the 
NHANES cohort concluded that cadmium exposure was associated with an increased risk of 
all-cause and cardiovascular disease mortality among men, but not women (Menke et al., 
2009). An  analysis of the 1999-2004 NHANES cohort found no differences in the 
association between cadmium exposure all-cause and CVD mortality by sex (Tellez-Plaza et 
al., 2012). A more recent systematic review of populations with low to moderate levels of 
cadmium exposure, however, found similar  associations between cadmium exposure and 
cardiovascular disease between men and women, but the relationship was not significant for 
women (Tellez-Plaza et al., 2013cc). Conversely, a longitudinal study conducted in a 
cadmium contaminated area of Japan suggested that high levels of exposure to cadmium led 
to excess risk of mortality among women but not in men (Uetani et al., 2007). Whilst sex 
specific risk was suggested in these studies the results were inconsistent and the differential 
associations by sex may represent chance findings. Barregard et al., (2016) investigated the 
relationship between blood cadmium and incident cardiovascular disease (CVD) in men and 
women in Sweden and found increased hazard ratios for all CVD events for participants in 
the highest exposure quartile.  
 
Mechanistically, cadmium exposure has been shown to elicit endothelial damage both in vitro 
and in murine models, with accelerated plaque formation observed (Knoflach et al., 2011; 
Messner et al., 2009). Cadmium exposure was found to be associated with the development 
of atherosclerotic plaques in 64 year old Swedish women after a 5 year follow up (Fagerberg 
et al., 2012), thus providing evidence of the pro-atherogenic potential effects of cadmium 
exposure. 
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Longitudinal studies of cadmium exposure and mortality are scarce, particularly in those with 
low levels of exposure. Given that women are known to have higher levels of cadmium 
exposure (Vahter et al., 2007) the contradictory results regarding the association between 
cadmium exposure and all-cause and CVD mortality in women, suggests that more studies 
focussed on women are warranted, especially older women. Furthermore, there have been 
limited studies on the relationship between cadmium exposure and non-fatal cardiovascular 
events. 
 
CVD remains the number one cause of mortality in Australia and globally (Australian Bureau 
of Statistics [ABS], 2014; World Health Organization [WHO], 2013). Therefore, it is 
important to identify factors that increase the risk of developing CVD. The objective of this 
study was to examine the association between cadmium exposure and the incidence of 
mortality, cardiovascular mortality and (non-fatal) cardiovascular events in 14.5 year follow 
up of 1359 elderly Western Australian women.  Coronary heart disease (CHD), stroke or 
cerebrovascular accident (CVA), heart failure (HF) and peripheral arterial disease (PAD), 
collectively known as atherosclerotic vascular disease (ASVD), were examined, as well as 
all-cause mortality. 
 
Methods 
Study population 
Participants of this study (n = 1500) were women randomly recruited in the Perth 
metropolitan region from the Australian electoral roll in 1998. They were initially 
randomised into a 5-year, double-blinded, placebo-controlled calcium intervention trial of 
1.2g of elemental calcium in the form of two tablets of calcium carbonate taken daily, or an 
identical placebo (Prince et al., 2006). Participants were aged ≥70 years, ambulant and 
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expected survival of at least 5-years.  Participants were then followed for an additional 10-
year observational extension study using the WA Data Linkage System (WADLS). At 
baseline written informed consent was obtained from all participants for the study and access 
to electronic health records. The Human Research Ethics Committee of the University of 
Western Australia approved the study protocol and consent form (approval number 
05/06/004/H50). The Human Research Ethics Committee of the Western Australian 
Department of Health (DOHWA HREC) also approved the data linkage study (approval 
number #2009/24) and Edith Cowan University approved the current analysis (project 
number 12120). 
  
Biochemistry 
Baseline second morning void urine samples were collected in 1998 from 1359 participants, 
frozen and stored at -20 °C and available for analysis. These samples were collected when 
participants attended a clinic appointment. Participants had all been advised to be well 
hydrated prior to the appointment. In 2014, samples were thawed and prepared for metals 
analysis at Edith Cowan University, Joondalup, Western Australia. Metal free polypropylene 
tubes and pipette tips were used during sample preparation. Four hundred microlitres of urine 
was diluted 1 in 10 in 2% nitric Acid (Suprapur, Merck). Seven standards were prepared over 
the range of 0.02 to 500 mg/L in 2% nitric acid from stock standards containing elements of 
interest. An internal standard (containing Sc, Ge, Y, Rh, Te), was also prepared along with 
certified reference material (urine ClinChek level I and II, Recipe). The standards and 
controls were then diluted as per samples. Simultaneously, verification standards ICP-MS-E 
(High Purity Standards) of 2, 50, 100 mg/L were prepared in 2% nitric acid. The samples 
were analysed on a Thermo Fisher iCAP Q ICP-MS using an autosampler (Thermo Scientific 
Inc., New York, United States). New peristaltic pump tubing was used with each batch and 
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the rinse solution used was Merck Nitric acid 2% Suprapur with 50 mL/L of Triton X 
(Merck). Calibration checks were run every 20 samples; if check samples outside 
calibrations, new calibration was performed. New calibration curves were run routinely every 
60 samples. 
 
Urinary creatinine was measured by the Jaffe reaction using an Abbott Architect c16000 auto 
analyser (Abbott Laboratories, Illinois, USA). Urine specific gravity was measured using an 
Atago Master Refractometer (Atago Co., Tokyo, Japan), at the School of Medical and Health 
Sciences, Edith Cowan University. 
   
A Hitachi 917 auto analyser (Roche Diagnostics, Mannheim, Germany) was used to measure 
total cholesterol, high-density lipoprotein cholesterol (HDLC) and serum triglyceride 
concentrations. Low-density lipoprotein cholesterol (LDLC) was calculated using 
Friedewald’s method (Friedewald et al., 1972). The Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation was used to calculate estimated glomerular filtration rate 
(eGFR) using serum creatinine (Levey et al., 2009).  
 
Baseline assessment 
Smoking status was coded as non-smoker (i.e. never smoked) or former /current smoker (ever 
smoked) if they had consumed more than 1 cigarette per day for more than 3 months at any 
time in their life. Sixty women with a history of smoking provided incomplete smoking 
history records and were given a value of median pack years from the whole cohort. Body 
weight (kg) was measured using electronic scales (August Sauter GmbH D-7470 Albstadt 1 
Ebingen) to the nearest 0.1 kg with participants wearing light clothes and no shoes. Height 
(m) was measured using a wall-mounted stadiometer (Holtain Limited, Crymych, Dyfed, 
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Britain) to the nearest 0.1 cm without socks or shoes. Body mass index (BMI) was calculated 
using the following equation = weight (kg) / [height (m)] 2. Prevalent diabetes and 
hypertension, and the use of cardiovascular medications (anti-hypertensive agents, statins and 
low dose aspirin) were available from the demographic questionnaire. Systolic (SBP) and 
diastolic blood pressure (DBP) were measured using the right arm, after the subject had been 
reclined and rested for 5 minutes, using a mercury column manometer.  
 
Prevalent atherosclerotic vascular disease at baseline was determined retrospectively from 
hospital discharge data 1980-1998 using the Western Australian Data Linkage System 
(WADLS), a population-based data linkage system, using diagnosis codes from the 
International Classification of Diseases, Injuries and Causes of Death Clinical Modification 
(ICD-9-CM) (World Health Organization., 1977). These codes included ischemic (coronary) 
heart disease (ICD-9-CM codes 410-414); heart failure (ICD-9-CM code 428); 
cerebrovascular disease excluding haemorrhage (ICD-9-CM codes 433-438); and peripheral 
arterial disease (ICD-9-CM codes 440-444).  
 
Common Carotid Artery Intima-Media Thickness and Carotid Focal Plaques 
Common carotid artery intimal medial thickness (CCA‐IMT) and the presence of carotid 
focal plaques were determined at year 3 (2001) described elsewhere (Ivey et al., 2011). 
Briefly, six images taken from three different angles (anterolateral, lateral, and posterolateral) 
were examined and the CCA-IMT from each image was averaged to give an overall mean 
CCA‐IMT and maximum CCA-IMT. A short‐term precision study with repeat IMT 
measurements yielded a coefficient of variation of 5.98% as described previously (Bonnick et 
al., 2001). The complete carotid tree (common carotid artery, carotid bulb, internal and 
external carotid) was then examined for the presence of focal plaque, defined as an area of 
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focal increased thickness (≥1mm) of the intima-media layer. Severity of carotid plaque was 
further dichotomized by the degree of carotid stenosis as either none to minimal (<25%) or 
moderate to high (≥25%) (Wilson et al., 1997). 
 
Outcome variables 
The Western Australian Data Linkage System (WADLS) provided linked data for the study. 
WADLS combines seven core databases including inpatient hospital morbidity, inpatient and 
records and includes working links with special-purpose health service and research 
databases dating back to as early as 1966 (Holman et al., 2008). The quality of WADLS 
linkage has been rigorously assessed by comparison with clerical investigation with estimates 
of invalid links (false-positives) and missed links (false-negatives) occurring in 0.11% of 
records (Holman et al., 1999). Data for all hospitalisations from baseline (1998) until 14.5 
years (2013) after their baseline visit was provided by the Hospital Morbidity Data Collection 
(HMDC) while deaths were provided by the Mortality Register, both of which are regularly 
audited (Holman et al., 1999). . Therefore, if the elderly women remained in Western 
Australia we had complete follow-up for all hospitalizations and deaths over 14.5 years.  
Principal discharge diagnosis data from the Hospital Morbidity Data Collection was used to 
ascertain hospitalizations as the validity of these codes is higher than the additional discharge 
diagnoses fields (Jamrozik et al., 2001). International Classification of Diseases, Injuries 
and Causes of Death (ICD) multiple cause of death were determined from the coded death 
certificate using information in Parts 1 and 2 of the death certificate or all diagnosis text 
fields from the death certificate where ICD 10 coded death data were not yet available. 
ASVD deaths were defined using the primary diagnosis codes from the International 
Classification of Diseases, Injuries and Causes of Death: Clinical Modification (ICD-9-CM) 
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and the International Statistical Classification of Diseases and Related Health Problems, 10th 
Revision, Australian Modification (ICD-10-AM) between 1998 and 2013, inclusive.  The 
following ICD9-CM and ICD10-AM codes were identified and utilised as part of the study: 
coronary heart disease (ICD-9-CM 410-414, ICD10-AM I20-I25), heart failure (ICD-9-CM 
428, ICD10-AM I50), peripheral arterial disease excluding haemorrhagic (ICD9-CM 440-
444, ICD10-AM I70-I74) and cerebrovascular disease excluding haemorrhagic (ICD-9-CM 
433-438, ICD10-AM I63-I69). All-cause mortality was not grouped. Outcomes relating to the 
incidence of non-fatal CVD events were also used, in addition to CVD mortality. The event 
outcomes (ASVD event, coronary heart disease event, heart failure event, cerebrovascular 
disease event, and peripheral arterial disease event) included the fatal cases as well as 
hospitalisations linked to the respective disease codes. The validity of the diagnoses of 
myocardial infarction from HMDC, CHD death from the death registry and heart failure from 
the HMDC have been previously reported (Jamrozik et al., 2001; Teng et al., 2008). 
 
Statistical methods 
All statistical analyses were performed in IBM SPSS Statistics, Version 22.0 (2012, Armonk, 
NY: IBM Corp).  Urinary cadmium was positively skewed and transformed using natural 
logarithm. Samples of urine that had concentrations below the limit of detection (LOD) 
(<0.05 µg/L) were assigned a value half of the LOD (Liu et al., 1997).  
Urinary cadmium concentrations were grouped into tertiles and changes in demographic and 
health characteristics across tertiles were determined using Kruskal Wallis and Chi-squared 
analysis. Logistic regression was used to generate odds ratios (with 95% confidence 
intervals) for the presence of carotid focal plaques. Hazard ratios (with 95% confidence 
intervals) were estimated for all-cause mortality, CVD mortality and CVD event end points 
using Cox proportional hazards regression. Urinary cadmium concentrations were introduced 
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into regression models as tertiles or as continuous ln-transformed concentrations. The p value 
for the linear trend for the tertile models was calculated by running the models with the 
median urinary cadmium value for each tertile. Three statistical models were generated, with 
progressive adjustment for the following variables at baseline. Model 1 was adjusted for age 
and calcium treatment (yes/no). Model 2 was further adjusted for BMI, hypertension 
(yes/no), eGFR (ml/min/1.73m2), prevalent ASVD (yes/no), diabetes (yes/no), low dose 
aspirin use (yes/no), statin use (yes/no). Model 3 was further adjusted for smoking status 
(ever/never) and cumulative dose (pack years). Participants were excluded if they had 
incomplete data for urinary cadmium or any of the confounders (for eGFR 132 participants 
had missing data, for BMI one participant had missing data and 7 had not responded 
regarding smoking status), leaving a sample size of 1219 in the final models. Models 
including urinary creatinine or specific gravity as a covariate were also run (supplementary 
data). As a sensitivity analysis Cox regression models were re-run excluding participants with 
urinary cadmium concentrations ≥10µg/L (n= 4), the findings remained unchanged (data not 
shown). Models were also re-run excluding participants with prevalent ASVD at baseline, to 
assess the relationship between urinary cadmium and incident ASVD. 
 
Results 
Urinary cadmium concentrations were low in this cohort with a mean concentration of 0.38 
µg/L and median of 0.18 µg/L (Table 1).  Cadmium concentrations were below the limit of 
detection in 13.8% of participants. Only 18 participants had urinary cadmium concentrations 
≥2 µg/L. Urine samples were second morning void samples collected when the participants 
were well hydrated and were dilute, with 73% of samples having a urinary creatinine 
concentrations of <0.3 g/L. Urinary specific gravity was also very low in this population 
(median 1.005, range 1.001-1.029). To avoid potential artificial inflation of cadmium 
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exposure, the unadjusted cadmium concentrations are presented. However, models were also 
run including specific gravity and creatinine as covariates and these are presented in 
Supplementary tables 1 and 2. 
 
The mean age for this sample of elderly women was 75.2 (± 2.7) years, with two thirds of 
participants being overweight or obese (BMI > 25.0 kg/m2). One in five (23.2%) participants 
entered the study with prevalent CVD and one in eight had prevalent ASVD (13%). Thirty 
seven percent of participants reported being a current or former smoker, and significant 
increases in the incidence of smokers, and also the number of pack years smoked, were seen 
across the tertiles of urinary cadmium (Table 2). A difference in estimated glomerular 
filtration rate (eGFR) was also apparent across the tertiles. Participants in the highest two 
tertiles of urinary cadmium concentration had higher concentrations of low density 
lipoprotein (LDL) cholesterol than those with urinary cadmium concentrations ≤ 0.115 µg/L, 
however, this relationship was not significant (Table 2). Sixty two per cent of participants in 
the highest urinary cadmium tertile had hypertension at baseline, compared with 55% in the 
lowest tertile. Interestingly, significant differences in the presence of plaques, measured 3 
years after baseline urine collection, were detected across the tertiles of urinary cadmium, 
with 45% of those in the highest tertile scoring positively for the presence of plaques, 
compared with 51% in the lowest tertile. Fifteen percent of participants had moderate to 
severe (≥25%) plaques identified at year 3 of the study. There were no differences in plaque 
severity across the tertiles of baseline urinary cadmium. Logistic regression revealed a 
decreased odds of having a plaque associated with increased urinary cadmium 
concentrations. In an adjusted model there was a 41% reduction in the odds of having a 
plaque for those in the highest tertile of urinary cadmium (Table 3). 
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Over a 14.5 year follow up period 479 participants (39%) died, with the number of deaths 
due to ASVD, CHD, heart failure, PAD and cerebrovascular accident 256, 152, 71, 16 and 
99, respectively. The number of events (including both hospitalisations and deaths) for 
ASVD, CHD, heart failure, PAD and cerebrovascular accident were 529, 316, 144, 69 and 
207, respectively. In fully adjusted models, urinary cadmium concentrations were associated 
with cardiovascular disease events, with a ln unit increase in urinary cadmium concentration 
(equivalent to a ~2.7 fold increase) associated with a 17% increase in risk of heart failure 
events (Table 4). Urinary cadmium concentrations were also positively associated with 
increased mortality. In models adjusted for BMI, hypertension (yes/no), eGFR 
(ml/min/1.73m2), prevalent ASVD (yes/no), diabetes (yes/no), low dose aspirin use (yes/no) 
and statin use (yes/no), every unit increase in ln transformed urinary cadmium concentration 
was associated with a hazard ratio of 1.11 (95% CI 1.02-1.20) for all-cause mortality, 1.13 
(95% CI 1.02-1.27) for ASVD mortality and 1.37 (95% CI 1.12-1.68) for heart failure 
mortality (Table 5). However, when these models were further adjusted for smoking history, 
only the relationship between urinary cadmium and heart failure death remained (HR 1.36 
(95% CI 1.11-1.67), demonstrating the importance of smoking as a confounder. In analysis 
using tertiles of urinary cadmium concentrations and adjusted for cumulative smoking dose, 
those in the highest tertile had an increased risk of heart failure mortality with a hazard ratio 
of 2.30 (95% CI 1.25-4.25), indicating a more than 2 fold increase in risk, noting the wide 
confidence intervals (Table 5). No significant relationships were observed between urinary 
cadmium and mortality or events for coronary heart disease, stroke or peripheral artery 
disease (Tables 4 and 5). However the numbers of cases of PAD related mortality was small 
(n=16) which precluded a detailed analysis (data not shown) and is likely to have made 
hazard ratios for this outcome unstable.  
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Urinary specific gravity measurements and creatinine concentrations were low in this cohort. 
However, when either specific gravity or urinary creatinine were added as a covariate this 
attenuated the relationship between urinary cadmium and the outcomes total mortality, 
ASVD and heart failure mortality and heart failure event (HR 1.04 95% CI 0.95-1.14; 1.02 
95% CI 0.90-1.17; 1.20 95% CI 0.94-1.54; 1.14 95% 0.96-1.35, respectively, including 
creatinine), (Supplementary Data Tables S1 and S2). Specific gravity was itself only a 
significant predictor in models for total mortality, ASVD mortality and heart failure 
mortality. 
 
Sensitivity analysis was conducted by removing all participants with prevalent ASVD 
(n=152) at baseline from the models. Whilst no relationship was present between urinary 
cadmium concentrations and all-cause mortality or ASVD mortality, the relationship with 
heart failure mortality remained (multivariate adjusted hazard ratio comparing highest to 
lowest tertile of 1.99 (95% CI 1.02-3.89) and 1.96 (95% CI 1.00-3.85) for models 2 and 3, 
respectively). A second sensitivity analysis was conducted excluding participants with 
outlying urinary cadmium concentrations ≥10µg/L (n=4). The results and interpretation of the 
models was unchanged. 
 
Amongst never smokers there was a 29% increased risk of heart failure mortality associated 
with a one ln unit increase in urinary cadmium, noting the wide confidence intervals HR 1.29 
(95% CI 1.01-1.63). However, this relationship was also attenuated by adjustment for urinary 
creatinine (HR 1.19 (95% CI 0.72-1.97), indicating that the results must be interpreted with 
caution.  
 
Discussion 
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In this cohort of elderly Australian women, urinary cadmium concentrations were associated 
with increased risk of heart failure hospitalisations and mortality, independent of age, 
smoking history and diabetes. The robustness of this association was confirmed in a 
sensitivity analysis excluding women with prevalent ASVD. However, attempts to adjust for 
urinary dilution weakened the associations between urinary cadmium and cardiovascular 
outcomes in this cohort. 
 
The concentrations of urinary cadmium in this study were low, with a median concentration 
of 0.18 µg/L, indicating lower exposure than pregnant and older women in recent Australian 
studies (Callan et al., 2015; Hinwood et al., 2013). In contrast to the work of Fagerberg et al., 
(2012), no increase in the presence, or severity, of atherosclerotic plaques was seen with 
increasing urinary cadmium concentrations in this cohort. In fact, contrary to previous work, 
a decrease in the odds of having a carotid focal plaque was found to be associated with 
increased urinary cadmium. The reasons for this discrepancy are unclear, however, the 
Swedish study did report that the association between cadmium and atherosclerotic plaques 
was only present in multivariate models when blood cadmium, not urine, was used as the 
measure of exposure, which may indicate that recent cadmium exposure is more relevant to 
plaque prevalence than long term cadmium exposure. Similarly, no associations were 
observed between blood lipid profiles and urinary cadmium, which differs from the work of 
Kim et al., (2012) in a Korean population. Although there was a higher incidence of 
diagnosed hypertension at baseline in participants in the highest tertile of urine cadmium in 
this study, no association was observed between urinary cadmium and blood pressure similar 
to the results of Staessen et al., (2000). One explanation may be the relatively high frequency 
of anti-hypertensive medication use in our cohort (43%).  
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In fully adjusted multivariate models, urinary cadmium was not associated with a significant 
increase in all-cause mortality in this cohort. Most of the longitudinal studies of cadmium 
exposure and all-cause or cardiovascular mortality which have presented results for women  
in cohorts from the US (both NHANES and native American communities) or Japan, with 
limited studies on cohorts outside these areas. The two longitudinal studies that analyse the 
NHANES cohort report non-significant relationships between urinary cadmium 
concentrations and all-cause, cardiovascular and coronary heart disease mortality in women 
(Menke et al., 2009; Tellez-Plaza et al., 2012). In a cohort residing in a cadmium 
contaminated region of Japan, increased urinary cadmium was found to be associated with 
increased all-cause, cardiovascular disease and stroke mortality in women (Li et al., 2011; 
Nakagawa et al., 2006). Similarly, an increased risk of all-cause mortality was reported in 
women in non-polluted areas of Japan (Suwazono et al., 2014). In women from native 
American communities increased urinary cadmium was found to be associated with increased 
risk of incident cardiovascular disease, coronary heart disease, and peripheral artery disease, 
but not incident stroke or heart failure (Tellez-Plaza et al., 2013aa; Tellez-Plaza et al., 
2013bb). The reasons for differences in the results presented in this study are unclear, 
however, the native American women (1750 participants) were younger than those in our 
cohort, with a mean age at baseline of 55.9 years. A Swedish study of post-menopausal 
women reported an increased risk of peripheral artery disease with increased urinary 
cadmium concentrations. Despite the relatively small sample size in the Swedish cohort (458 
participants), the number of peripheral artery disease cases (55) was greater than in our study 
which may explain our failure to observe an increased risk of peripheral artery disease or 
related mortality (Fagerberg et al., 2013).  
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The mechanism by which cadmium exposure may increase the risk of heart failure is unclear. 
Although not redox active, cadmium has been found to elicit oxidative stress in numerous 
studies. Chronic cadmium exposure has been found to promote oxidative stress and 
endothelial damage in rat aortas (Almenara et al., 2013). Given that clinical and experimental 
studies have identified an increase in oxidative stress and reactive oxygen species in heart 
failure patients (reviewed by (Tsutsui et al., 2011), this may represent a potential mechanistic 
pathway, however the relationship between cadmium exposure and heart failure requires 
further investigation. 
 
There were a number of strengths to this study including the long (14.5 year) follow up 
period and the ability to analyse both fatal and non-fatal cardiovascular events. Several of the 
previous studies investigating cadmium exposure and cardiovascular outcomes have been 
restricted to cardiovascular mortality, which represents a distinct subset of cardiovascular 
disease events. Also by excluding participants with prevalent ASVD at baseline we were able 
to examine incident cardiovascular disease, although the relationship between urinary 
cadmium and incident cardiovascular disease was only significant for heart failure. There 
have been a limited number of previous studies which have focused specifically on the 
effects of low cadmium exposure in older women. Furthermore the ability to adjust the 
analyses for a number of baseline characteristics and known cardiovascular risk factors is a 
strength of the study. However it is possible that the lifetime cumulative effects of smoking 
may not have been adequately captured in the adjustment variables. Similarly, cotinine 
determinations were not available in the present study, thus residual confounding by second hand 
smoke cannot be discarded as a contributor to cadmium concentrations in these women. 
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In terms of limitations, as this is an observational study causality cannot be determined. 
Secondly, in this study urine samples were morning second void samples from well hydrated 
participants. Thus a large proportion of samples were dilute with urinary creatinine 
concentrations <0.3 g/L, indicating that creatinine adjustment was not advisable in this cohort 
(WHO, 1996). This lack of adjustment may have led to exposure misclassification and a 
failure to adequately adjust for kidney function, which is itself impacted by cadmium 
exposure. Regression models were adjusted for estimated glomerular filtration rate to try to 
adjust for (chronic) kidney function, however, given that the inclusion of either specific 
gravity or creatinine in the models as covariates attenuated the relationships between 
cadmium and cardiovascular outcomes (Supplementary Data Tables 1 and 2) this suggests 
that unresolved confounding from kidney function was present in this study. However given 
the fact that the women were elderly and likely to have reduced creatinine excretion and 
specific gravity (Davies et al., 2002; Moriguchi et al., 2005), adjustment of urinary cadmium 
concentrations in this cohort may have led to overestimation of exposure, which is why a 
conservative approach without adjustment was adopted for the initial models, with further 
models presented in Supplementary data for completeness. Nonetheless, the fact that 
creatinine attenuated the associations between urinary cadmium and cardiovascular outcomes 
in this cohort indicates that the results are only suggestive and require confirmation in a 
cohort in which first morning void samples are available for analysis. Thirdly, most of the 
observed associations were became non-significant after adjusting for self-reported smoking 
history suggesting the association may not be independent of smoking history. A further 
limitation is that there was missing data in a number of the covariates used to adjust the 
models which led to a reduction in sample size and power, and may have introduced bias. 
However the covariates included in the model were known predictors of mortality and 
cardiovascular disease and therefore allowed for a comprehensive analysis of the relationship 
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of low cadmium exposure with all-cause mortality and cardiovascular disease, albeit in a 
reduced study cohort. Finally, for heart failure events and in particular heart failure deaths, 
there were few events. As such the findings should be interpreted with caution until the 
relationship between urinary cadmium and heart failure events can be confirmed in other 
prospective studies.   
 
Conclusions 
 In this cohort of elderly women with low cadmium exposure, increased urinary cadmium 
was associated with increased heart failure mortality and non-fatal heart failure events over a 
14.5 year follow up period, although adjustment for urinary specific gravity or creatinine 
attenuated these relationships, therefore the results must be interpreted with caution. The 
relationship with heart failure mortality was observed in never smokers, although residual 
confounding by second hand smoke exposure cannot be ruled out, these results suggest that 
low level (dietary) cadmium exposure may be associated with increased heart failure 
mortality in women, however given the dilution of the urine samples in this study these 
findings require confirmation in other cohorts. Given the low urinary cadmium 
concentrations in this study the results appear to support the concept that cadmium exposure 
may be a risk factor for cardiovascular outcomes, however the importance of confounding 
from kidney function was evident. 
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Table 1. Urinary cadmium concentrations in elderly women (n=1219). 
  Percentiles 
Urinary measurement Mean 5th 25th 50th 75th 95th 
Cadmium unadjusted (µg/L) 0.37 <0.05 0.09 0.18 0.32 0.95 
Cadmium Adjusted (µg/g creatinine)* 0.94 0.12 0.44 0.65 1.06 2.30 
IQR = interquartile range 
*Creatinine adjusted results presented only for women with urinary creatinine >0.3g/L (n=327) 
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Table 2. Baseline characteristics of the study participants overall and expressed by tertiles of urinary cadmium (n = 1219, unless otherwise 
specified). 
  Cadmium Tertiles (µg/L)  
 Overall ≤ 0.115 > 0.115 – 0.255 > 0.255 p value 
Age, (years)a 75.2 ± 2.7 75.0 ± 2.7 75.2 ± 2.7 75.4 ± 2.7 0.084 
BMI, (Kg/m2)a 27.1 ± 4.7 26.9 ± 4.9 27.1 ± 4.3 27.4 ± 4.8 0.232 
Smoking                  
Ever smokerb 451 (37) 122 (30) 149 (37) 180 (44) <0.001* 
Pack yearsa 7.2 ± 16.6 4.00 ± 10.2 6.3 ±14.2 11.4 ±22.2 <0.001* 
Cholesterol mg/dLa,e 226.8 ± 42.9 223.1 ± 43.8 228.7 ± 39.9 228.5 ± 44.7 0.185 
HDL cholesterol mg/dLa,e 56.2 ± 14.7 56.4 ± 15.6 56.4 ± 14.2 55.9 ± 14.2 0.954 
Triglycerides mg/dLa,e 138.4 ± 64.0 139.4 ± 68.7 138.8 ± 63.6 137.1 ± 59.7 0.932 
LDL cholesterol mg/dLa,e 142.5 ± 39.3 138.7 ± 38.8 144.2 ± 36.4 144.6 ± 42.1 0.151 
Mean systolic blood pressure (mmHg)a,e 137.7 ± 17.9 138.5 ± 19.0 137.8 ± 16.6 137.0 ± 18.0 0.832 
Mean diastolic blood pressure (mmHg)a,e 73.1 ± 11.0 72.6 ± 10.9 73.0 ± 10.4 73.7 ± 11.7 0.334 
Mean arterial pressure (mmHg)a,e 94.6 ± 11.7 94.5 ± 12.0 94.6 ± 10.9 94.8 ± 12.3 0.825 
Mean of mean intima-media thickness (mm)a,e 0.78 ± 0.13 0.78 ± 0.13 0.78 ± 0.12 0.77 ± 0.12 0.594 
Mean of maximum intima-media thickness (mm)a,e 0.92 ± 0.15 0.93 ± 0.16 0.92 ± 0.15 0.91 ± 0.15 0.524 
Presence of atherosclerotic plaqueb,c,d,e 472 (50) 158 (51) 172 (55) 142   (45) 0.032* 
Moderate to severe plaque (≥25%)d,e 138 (15) 45 (15) 48 (15) 45 (14) 0.919 
eGFR (ml/min/1.73 m2)a 66.5 ± 13.2 68.0 ± 13.0 65.5 ± 13.3 66.0 ± 13.5  0.019* 
Hypertensionb 688 (56) 223 (55) 214 (53) 251 (62) 0.024* 
Diabetesb 81 (6.6) 31 (7.6) 20 (4.9) 30 (7.4) 0.239 
Low dose aspirin useb 263 (22) 86 (21) 85 (21) 92  (23) 0.809 
Statin use 226 (19) 65 (16) 81 (20) 80 (20) 0.250 
Prevalent ASVDb 152 (13) 44 (11) 50 (12) 58 (14) 0.318 
amean ± standard deviation; bnumber (percentage); c(n=929); dmeasured at year 3, not baseline; eMissing data – n for cholesterol measures 
n=908, for blood pressure n=1180, intima-media thickness n=922 and presence of plaque n=937. 
p values were calculated using Kruskal-Wallis or Chi-squared tests. *Relationship is significant at the 0.05 level (2-tailed). 
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Table 3: Presence of carotid focal plaque (measured at year 3) by urinary cadmium concentration (n=937)* 
 Cadmium Tertiles (µg/L) Continuous 
≤ 0.115 > 0.115 – 0.255 > 0.255 
Model 1 1.00 1.14  (0.83 1.57) 0.73  (0.53 1.00) 0.90  (0.80 1.02) 
Model 2 1.00 1.16  (0.84 1.60) 0.68  (0.49 0.94) 0.89  (0.79 1.00) 
Model 3 1.00 1.11  (0.80 1.54) 0.59  (0.42 0.83) 0.85 (0.75 0.96) 
* Presented as Odds ratios (95% CI) 
Model 1 adjusted for age at baseline and calcium treatment (yes/no). Model 2 further adjusted for BMI, hypertension (yes/no), eGFR 
(ml/min/1.73m2), Prevalent ASVD (yes/no), diabetes (yes/no), low dose aspirin use (yes/no) and statin use (yes/no). Model 3 further adjusted for 
smoking status (ever/never) and cumulative dose (pack years). Bold values indicate significance at p <0.05. Continuous cadmium concentration 
per ln unit (equivalent to ~2.7 fold) increase in urinary cadmium. Further adjustment for urinary specific gravity had no impact on the 
interpretation of these models. 
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Table 4: Atherosclerotic vascular disease events (death or hospitalisation) Endpoints by Urine Cadmium Concentrations (n=1219)* 
 
 Cadmium Tertiles (µg/L)   
 
≤ 0.115 > 0.115 – 0.255 > 0.255 
p for 
trend 
Continuous p value 
 Atherosclerotic vascular disease event 
No. cases/noncases 165/408 184/405 180/406  529/1219  
Model 1 1.00 1.07    (0.84,    1.35) 1.13    (0.89, 1.43) 0.326 1.05    (0.97, 1.14) 0.245 
Model 2                                           1.00 1.06 (0.84, 1.34) 1.03 (0.82, 1.30) 0.878 1.03 (0.95, 1.13) 0.441 
Model 3 1.00 1.04 (0.82, 1.31) 0.99 (0.78, 1.25) 0.835 1.02 (0.93, 1.11) 0.673 
 Coronary heart disease event 
No. cases/noncases 99/408 111/405 106/406  316/1219  
Model 1 1.00 1.15 (0.88,   1.51) 1.09 (0.83, 1.43) 0.680 1.07 (0.97, 1.18) 0.203 
Model 2 1.00 1.14 (0.87, 1.51) 0.97 (0.74, 1.28) 0.622 1.04 (0.94, 1.15) 0.447 
Model 3 1.00 1.12 (0.85, 1.47) 0.92 (0.69, 1.21) 0.365 1.02 (0.92, 1.13) 0.697 
 Heart failure event 
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No. cases/noncases 39/408 46/405 59/406  144/1219  
Model 1 1.00 1.20 (0.78, 1.84) 1.57 (1.04, 2.35) 0.027 1.19 (1.03, 1.37) 0.019 
Model 2 1.00 1.24 (0.80, 1.91) 1.47 (0.98, 2.21) 0.071 1.17 (1.01, 1.36) 0.032 
Model 3 1.00 1.24 (0.80, 1.91) 1.46 (0.97, 2.21) 0.080 1.17 (1.01, 1.35) 0.039 
 Peripheral artery disease event 
No. cases/noncases 15/405 23/401 29/403  69/1215  
Model 1 1.00 1.47 (0.78,  2.77) 1.79 (0.97, 3.30) 0.079 1.18 (0.96, 1.45) 0.110 
Model 2 1.00 1.53 (0.81, 2.91) 1.70 (0.92, 3.15) 0.127 1.17 (0.95, 1.44) 0.133 
Model 3 1.00 1.45    (0.76,    2.75) 1.55   (0.83,    2.90) 0.231 1.15 (0.92,    1.43) 0.222 
 Cerebrovascular accident event 
No. cases/noncases 70/408 70/405 67/406  207/1219  
Model 1 1.00 1.00 (0.72, 1.39) 0.96 (0.69, 1.35) 0.807 1.01 (0.89, 1.14) 0.916 
Model 2 1.00 1.00 (0.72, 1.40) 0.90 (0.65, 1.27) 0.517 0.99 (0.88, 1.12) 0.894 
Model 3 1.00 1.00    (0.71,   1.40) 0.90    (0.64,    1.27) 0.528 1.00 (0.88,  1.13) 0.937 
*HRs (95% CI) 
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Model 1 adjusted for age at baseline and calcium treatment (yes/no). Model 2 further adjusted for BMI, hypertension (yes/no), eGFR 
(ml/min/1.73m2), Prevalent ASVD (yes/no), diabetes (yes/no), low dose aspirin use (yes/no) and statin use (yes/no). Model 3 further adjusted for 
smoking status (ever/never) and cumulative dose (pack years). *p value for linear trend calculated by running model with median value for each 
tertile. Bold values indicate significance at p <0.05. Continuous cadmium concentrations per ln unit (equivalent to ~2.7 fold) increase in urinary 
cadmium. 
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Table 5: Mortality Endpoints by Urine Cadmium Concentrations (n=1219)* 
 Cadmium Tertiles (µg/L)   
 ≤ 0.115 > 0.115 – 0.255 > 0.255 p for trend* Continuous p value 
 Total mortality 
No. cases/noncases 145/408 158/405 176/406  479/1219  
Model 1 1.00 1.10 (0.88, 1.38) 1.24       (0.99, 1.54) 0.058 1.12 (1.03, 1.21) 0.007 
Model 2 1.00 1.11 (0.88, 1.39) 1.19 (0.95, 1.48) 0.148 1.11 (1.02, 1.20) 0.014 
Model 3 1.00 1.06 (0.85, 1.34) 1.10 (0.87, 1.37) 0.463 1.08 (0.99, 1.17) 0.081 
 Atherosclerotic vascular disease mortality 
No. cases/noncases 70/408 90/405 96/406  256/1219  
Model 1 1.00 1.29 (0.94, 1.76) 1.38 (1.02, 1.88) 0.064 1.15 (1.03, 1.28) 0.011 
Model 2 1.00 1.29 (0.94, 1.77) 1.28 (0.94,  1.74) 0.207 1.13 (1.02, 1.27) 0.025 
Model 3 1.00 1.24 (0.90, 1.71) 1.21 (0.88,  1.66) 0.359 1.12 (1.00, 1.25) 0.055 
 Coronary heart disease mortality 
No. cases/noncases 42/408 57/405 53/406  152/1217  
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Model 1 1.00 1.36    (0.91,     2.03) 1.27 (0.85, 1.91) 0.379 1.12    (0.97,    1.28) 0.122 
Model 2 1.00 1.34 (0.89, 2.00) 1.15 (0.76, 1.73) 0.761 1.10 (0.95, 1.26) 0.214 
Model 3 1.00 1.31 (0.88, 1.97) 1.11 (0.74, 1.69) 0.880 1.09 (0.94, 1.26) 0.258 
 Heart failure mortality 
No. cases/noncases 15/408 19/405 37/406  71/1219  
Model 1 1.00 1.28   (0.65,    2.51) 2.49 (1.36, 4.54) 0.001 1.37 (1.13, 1.65) 0.001 
Model 2 1.00 1.28 (0.65, 2.54) 2.36 (1.29, 4.32) 0.002 1.37 (1.12, 1.68) 0.002 
Model 3 1.00 1.26 (0.63, 2.51) 2.30 (1.25, 4.25) 0.003 1.36 (1.11, 1.67) 0.003 
 Cerebrovascular accident mortality 
No. cases/noncases 30/408 36/405 33/406  99/1216  
Model 1 1.00 1.20 (0.74, 1.95) 1.11 (0.67, 1.82) 0.806 1.04 (0.87, 1.23) 0.703 
Model 2    1.00 1.18 (0.72, 1.92) 1.03 (0.62, 1.69) 0.939 1.02 (0.85,  1.22) 0.824 
Model 3 1.00 1.13 (0.69, 1.85) 0.96 (0.58,  1.59) 0.750 1.00 (0.83,  1.20) 0.975 
*HR (95% CI) 
Model 1 adjusted for age at baseline and calcium treatment (yes/no). Model 2 further adjusted for BMI, hypertension (yes/no), eGFR 
(ml/min/1.73m2), Prevalent ASVD (yes/no), diabetes (yes/no), low dose aspirin use (yes/no) and statin use (yes/no). Model 3 further adjusted for 
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smoking status (ever/never) and cumulative dose (pack years). *p value for linear trend calculated by running model with median value for each 
tertile. Bold values indicate significance at p <0.05. Continuous cadmium concentration per ln unit (equivalent to ~2.7 fold) increase in urinary 
cadmium. 
